In the period 2018 to 2022, a total of approximately *** men per 100,000 inhabitants died of cancers of all kinds in the United States, compared to an overall cancer death rate of *** per 100,000 population among women. This statistic shows cancer death rates in the U.S. for the period from 2018 to 2022, by type and gender.

Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

Breast cancer was the cancer type with the highest rate of death among females worldwide in 2022. That year, there were around 13 deaths from breast cancer among females per 100,000 population. The death rate for all cancers among females was 76.4 per 100,000 population. This statistic displays the rate of cancer deaths among females worldwide in 2022, by type of cancer.

The cancer type with the highest age-standardized mortality rate in Latin America and the Caribbean in 2022 was prostate cancer with 13.9 deaths per 100,000 population. Breast cancer ranked second, with a mortality rate of 13.2 people per 100,000 population. In that year, breast cancer was the cancer type with the highest prevalence in the region.

The United States Cancer Statistics (USCS) online databases in WONDER provide cancer incidence and mortality data for the United States for the years since 1999, by year, state and metropolitan areas (MSA), age group, race, ethnicity, sex, childhood cancer classifications and cancer site. Report case counts, deaths, crude and age-adjusted incidence and death rates, and 95% confidence intervals for rates. The USCS data are the official federal statistics on cancer incidence from registries having high-quality data and cancer mortality statistics for 50 states and the District of Columbia. USCS are produced by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), in collaboration with the North American Association of Central Cancer Registries (NAACCR). Mortality data are provided by the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System (NVSS).

BackgroundThe success of the “war on cancer” initiated in 1971 continues to be debated, with trends in cancer mortality variably presented as evidence of progress or failure. We examined temporal trends in death rates from all-cancer and the 19 most common cancers in the United States from 1970–2006.Methodology/Principal FindingsWe analyzed trends in age-standardized death rates (per 100,000) for all cancers combined, the four most common cancers, and 15 other sites from 1970–2006 in the United States using joinpoint regression model. The age-standardized death rate for all-cancers combined in men increased from 249.3 in 1970 to 279.8 in 1990, and then decreased to 221.1 in 2006, yielding a net decline of 21% and 11% from the 1990 and 1970 rates, respectively. Similarly, the all-cancer death rate in women increased from 163.0 in 1970 to 175.3 in 1991 and then decreased to 153.7 in 2006, a net decline of 12% and 6% from the 1991 and 1970 rates, respectively. These decreases since 1990/91 translate to preventing of 561,400 cancer deaths in men and 205,700 deaths in women. The decrease in death rates from all-cancers involved all ages and racial/ethnic groups. Death rates decreased for 15 of the 19 cancer sites, including the four major cancers, with lung, colorectum and prostate cancers in men and breast and colorectum cancers in women.Conclusions/SignificanceProgress in reducing cancer death rates is evident whether measured against baseline rates in 1970 or in 1990. The downturn in cancer death rates since 1990 result mostly from reductions in tobacco use, increased screening allowing early detection of several cancers, and modest to large improvements in treatment for specific cancers. Continued and increased investment in cancer prevention and control, access to high quality health care, and research could accelerate this progress.

BackgroundThe role of breast screening in breast cancer mortality declines is debated. Screening impacts cancer mortality through decreasing the number of advanced cancers with poor diagnosis, while cancer treatment works through decreasing the case-fatality rate. Hence, reductions in cancer death rates thanks to screening should directly reflect reductions in advanced cancer rates. We verified whether in breast screening trials, the observed reductions in the risk of breast cancer death could be predicted from reductions of advanced breast cancer rates.Patients and MethodsThe Greater New York Health Insurance Plan trial (HIP) is the only breast screening trial that reported stage-specific cancer fatality for the screening and for the control group separately. The Swedish Two-County trial (TCT)) reported size-specific fatalities for cancer patients in both screening and control groups. We computed predicted numbers of breast cancer deaths, from which we calculated predicted relative risks (RR) and (95% confidence intervals). The Age trial in England performed its own calculations of predicted relative risk.ResultsThe observed and predicted RR of breast cancer death were 0.72 (0.56–0.94) and 0.98 (0.77–1.24) in the HIP trial, and 0.79 (0.78–1.01) and 0.90 (0.80–1.01) in the Age trial. In the TCT, the observed RR was 0.73 (0.62–0.87), while the predicted RR was 0.89 (0.75–1.05) if overdiagnosis was assumed to be negligible and 0.83 (0.70–0.97) if extra cancers were excluded.ConclusionsIn breast screening trials, factors other than screening have contributed to reductions in the risk of breast cancer death most probably by reducing the fatality of advanced cancers in screening groups. These factors were the better management of breast cancer patients and the underreporting of breast cancer as the underlying cause of death. Breast screening trials should publish stage-specific fatalities observed in each group.

In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

Annual percent change and average annual percent change in age-standardized cancer mortality rates since 1984 to the most recent data year. The table includes a selection of commonly diagnosed invasive cancers and causes of death are defined based on the World Health Organization International Classification of Diseases, ninth revision (ICD-9) from 1984 to 1999 and on its tenth revision (ICD-10) from 2000 to the most recent year.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

Source: https://ourworldindata.org/cancer

The dataset titled "Cancer Types Causing Death," sourced from Our World in Data, provides a comprehensive overview of global cancer mortality trends. According to the dataset, lung cancer leads as the most fatal cancer worldwide, with approximately 1.8 million deaths in 2022, accounting for 18.7% of all cancer-related fatalities . Following lung cancer, colorectal cancer ranks second, causing about 900,000 deaths (9.3%), while liver cancer and breast cancer account for 760,000 (7.8%) and 670,000 (6.9%) deaths, respectively. Stomach cancer also remains a significant cause of death, with 660,000 fatalities (6.8%) .

The dataset highlights that lung cancer's prevalence is closely linked to tobacco use, particularly in regions like Asia. In contrast, breast cancer predominantly affects women, while colorectal cancer impacts both genders equally. Notably, the dataset indicates a decline in age-standardized death rates for certain cancers, such as stomach cancer, due to improved hygiene, sanitation, and antibiotic treatments targeting Helicobacter pylori infections . Our World in Data

Additionally, the dataset underscores the global disparity in cancer mortality, with approximately 70% of cancer deaths occurring in low- and middle-income countries . This disparity is attributed to factors like limited access to early detection, treatment, and preventive measures. The dataset serves as a valuable resource for understanding the global burden of cancer and the need for targeted public health interventions. World Health Organization

Cervical cancer (CC) is a public health problem with a high disease burden and mortality in developing countries. In Brazil, areas with low human development index have the highest incidence rates of Brazil and upward temporal trend for this disease. The Northeast region has the second highest incidence of cervical cancer (20.47 new cases / 100,000 women). In this region, the mortality rates are similar to rates in countries that do not have a health system with a universal access screening program, as in Brazil. Thus, this study aimed to analyze the effects of age, period and birth cohorts on mortality from cervical cancer in the Northeast region of Brazil. Estimable functions predicted the effects of age, period and birth cohort. The average mortality rate was 10.35 deaths per 100,000 women during the period analyzed (1980–2014). The highest mortality rate per 100,000 women was observed in Maranhão (24.39 deaths), and the lowest mortality rate was observed in Bahia (11.24 deaths). According to the period effects, only the state of Rio Grande do Norte showed a reduction in mortality risk in the five years of the 2000s. There was a reduction in mortality risk for birth cohorts of women after the 1950s, except in Maranhão State, which showed an increasing trend in mortality risk for younger generations. We found that the high rates of cervical cancer mortality in the states of northeastern Brazil remain constant over time. Even after an increase in access to health services in the 2000s, associated with increased access to the cancer care network, which includes early detection (Pap Test), cervical cancer treatment and palliative care. However, it is important to note that the decreased risk of death and the mortality rates from CC among women born after the 1960s may be correlated with increased screening coverage, as well as increased access to health services for cancer treatment observed in younger women.

The leading causes of death in the United States are heart disease and cancer. However, in 2022, COVID-19 was the fourth leading cause of death in the United States, accounting for around six percent of all deaths that year. In 2022, there were around 45 deaths from COVID-19 per 100,000 population.

Cardiovascular disease

Deaths from cardiovascular disease are more common among men than women but have decreased for both sexes over the past few decades. Coronary heart disease accounts for the highest portion of cardiovascular disease deaths in the United States, followed by stroke and high blood pressure. The states with the highest death rates from cardiovascular disease include Oklahoma, Mississippi, and Alabama. Smoking tobacco, physical inactivity, poor diet, stress, and being overweight or obese are all risk factors for developing heart disease.

Cancer

Although cancer is the second leading cause of death in the United States, like deaths from cardiovascular disease, deaths from cancer have decreased over the last few decades. The highest death rates from cancer come from lung cancer for both men and women. Breast cancer is the second deadliest cancer for women, while prostate cancer is the second deadliest cancer for men. West Virginia, Mississippi, and Kentucky lead the nation with the highest cancer death rates.

Mortality from all cancers, directly age-standardised rate, persons, under 75 years, 2004-08 (pooled) per 100,000 European Standard population by Local Authority by local deprivation quintile. Local deprivation quintiles are calculated by ranking small areas (Lower Level Super Output Areas (LSOAs)) within each Local Authority based on their Index of Multiple Deprivation 2007 (IMD 2007) deprivation score, and then grouping the LSOAs in each Local Authority into five groups (quintiles) with approximately equal numbers of LSOAs in each. The upper local deprivation quintile (Quintile 1) corresponds with the 20% most deprived small areas within that Local Authority. The mortality rates have been directly age-standardised using the European Standard Population in order to make allowances for differences in the age structure of populations. There are inequalities in health. For example, people living in more deprived areas tend to have shorter life expectancy, and higher prevalence and mortality rates of most cancers. Cancer accounts for nearly 30% of all deaths among men in England every year and nearly 25% of deaths among women every year1. Reducing inequalities in premature mortality from all cancers is a national priority, as set out in the Department of Health’s Vital Signs Operating Framework 2008/09-2010/112 and the PSA Delivery Agreement 183. However, existing indicators for premature cancer mortality do not take deprivation into account. This indicator has been produced in order to quantify inequalities in cancer mortality by deprivation. This indicator has been discontinued and so there will be no further updates. Legacy unique identifier: P01368

Background: Information on patient’s death is a major outcome of health-related research, but it is not always available in claim-based databases. Herein, we suggested the operational definition of death as an optimal indicator of real death and aim to examine its validity and application in patients with cancer.Materials and methods: Data of newly diagnosed patients with cancer between 2006 and 2015 from the Korean National Health Insurance Service—National Sample Cohort data were used. Death indicators were operationally defined as follows: 1) in-hospital death (the result of treatment or disease diagnosis code from claims data), or 2) case wherein there are no claims within 365 days of the last claim. We estimated true-positive rates (TPR) and false-positive rates (FPR) for real death and operational definition of death in patients with high-, middle-, and low-mortality cancers. Kaplan−Meier survival curves and log-rank tests were conducted to determine whether real death and operational definition of death rates were consistent.Results: A total of 40,970 patients with cancer were recruited for this study. Among them, 12,604 patients were officially reported as dead. These patients were stratified into high- (lung, liver, and pancreatic), middle- (stomach, skin, and kidney), and low- (thyroid) mortality groups consisting of 6,626 (death: 4,287), 7,282 (1,858), and 6,316 (93) patients, respectively. The TPR was 97.08% and the FPR was 0.98% in the high mortality group. In the case of the middle and low mortality groups, the TPR (FPR) was 95.86% (1.77%) and 97.85% (0.58%), respectively. The overall TPR and FPR were 96.68 and 1.27%. There was no significant difference between the real and operational definition of death in the log-rank test for all types of cancers except for thyroid cancer.Conclusion: Defining deaths operationally using in-hospital death data and periods after the last claim is a robust alternative to identifying mortality in patients with cancer. This optimal indicator of death will promote research using claim-based data lacking death information.

This table contains 52020 series, with data for years 1996 - 1996 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (170 items: Canada; Newfoundland and Labrador; Health and Community Services St. John's Region; Newfoundland and Labrador; Health and Community Services Eastern Region; Newfoundland and Labrador ...), Sex (3 items: Both sexes; Males; Females ...), Selected causes of death (ICD-9) (17 items: Total; all causes of death; All malignant neoplasms (cancers);Lung cancer; Colorectal cancer ...), Characteristics (6 items: Number of deaths; Low 95% confidence interval; number of deaths; Mortality; High 95% confidence interval; number of deaths ...).

The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2022, the death rate from breast cancer had dropped from 31.9 to 18.7 per 100,000 population. Cancer is a serious public health issue in the United States. As of 2021, cancer is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women had the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of the early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

This data shows premature deaths (Age under 75) from all Cancers, numbers and rates by gender, as 3-year moving-averages. Cancers are a major cause of premature deaths. Inequalities exist in cancer rates between the most deprived areas and the most affluent areas. Directly Age-Standardised Rates (DASR) are shown in the data (where numbers are sufficient) so that death rates can be directly compared between areas. The DASR calculation applies Age-specific rates to a Standard (European) population to cancel out possible effects on crude rates due to different age structures among populations, thus enabling direct comparisons of rates. A limitation on using mortalities as a proxy for prevalence of health conditions is that mortalities may give an incomplete view of health conditions in an area, as ill-health might not lead to premature death. Data source: Office for Health Improvement and Disparities (OHID), indicator ID 40501, E05a. This data is updated annually.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

This table contains 33048 series, with data for years 2000/2002 - 2010/2012 (not all combinations necessarily have data for all years), and was last released on 2016-03-16. This table contains data described by the following dimensions (Not all combinations are available): Geography (36 items: Total, census metropolitan areas; St. John's, Newfoundland and Labrador; Halifax, Nova Scotia;Moncton, New Brunswick; ...), Sex (3 items: Both sexes; Males; Females), Indicators (2 items: Mortality; Potential years of life lost), Selected causes of death (ICD-10) (17 items: Total, all causes of death; All malignant neoplasms (cancers); Colorectal cancer; Lung cancer; ...), Characteristics (9 items: Number; Low 95% confidence interval, number; High 95% confidence interval, number; Rate; ...).